# Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

> **NCT04139772** · PHASE3 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Castration-resistent Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Abiraterone Acetate or Enzalutamide

## Key facts

- **NCT ID:** NCT04139772
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04139772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04139772, "Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04139772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*